Posts

The U.S. national public health agency said on Friday that Omicron subvariants BQ.1 and BQ.1.1 were estimated to account for about 44.2% of COVID-19 cases in the country for the week ending Nov. 12, compared with 32.6% in the previous week.

GSK’s oncology business suffers fresh blow with Zejula setback By Natalie Grover and Pushkala Aripaka Nov 11 (Reuters) – Britain’s GSK (GSK.L) said on Friday it would limit the use of its ovarian cancer drug Zejula in the United States as a second treatment option to keep cancer at bay in patients whose tumors carry […]

An estimated 3.08 million U.S. middle and high school students reported using a tobacco product in the last 30 days in 2022, down from 4.47 million in 2020 and 6.20 million in 2019, according to government data released on Thursday.

The annual price of a newly-launched cancer drug in the United States averaged $283,000 last year, a 53% increase from 2017, according to a new report from U.S. Democratic Representative Katie Porter, a consumer bankruptcy law professor running for re-election in California.

Leading consulting firm McKinsey & Co. has agreed to settle claims by hundreds of U.S. local governments and school districts around the country that it fueled an epidemic of opioid addiction through its work for bankrupt OxyContin maker Purdue Pharma LP and other drug companies.

People with severely weakened immune systems, such as those infected with HIV, can experience severe symptoms and even die from a monkeypox infection, according to a U.S. study released on Wednesday.

Daily global COVID-19 infections are projected to rise slowly to about 18.7 million by February from the current 16.7 million average daily cases, driven by the northern hemisphere’s winter months, the University of Washington said in an analysis.

An estimated 2.55 million U.S. middle and high school students reported using e-cigarettes during the early part of this year, health officials said on Thursday, a level they described as concerning.

The Centers for Disease Control and Prevention (CDC) said on Monday it had ended its COVID-19 country travel health notices as fewer countries reported enough data for accurate assessments.

Amylyx Pharmaceuticals Inc. said on Friday it has set the list price of its newly approved drug to slow the progression of amyotrophic lateral sclerosis (ALS) at about $158,000 per year in the United States.